First human trial launches for Hemay5259: a new Extended-Release drug candidate
Knowledge-focused
Not yet recruiting
This early-stage trial evaluates the safety, tolerability, and pharmacokinetics (how the body absorbs and processes the drug) of Hemay5259 extended-release tablets in healthy adults aged 18 to 55. Participants receive either the drug or a placebo, and the study also examines how …
Phase: PHASE1 • Sponsor: Hemay Pharmaceutical PTY. LTD. • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC